PFIZER’S LORBRENA EXTENDS LIFE FOR PATIENTS WITH RARE LUNG CANCER
Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a type of non-small cell lung cancer with a genetic mutation called ALK. Non-small cell lung cancers account for about 85% of lung cancer diagnoses, and…